阿司匹林通过微调由GPIHBP1调节的CD36局部化来阻碍非小细胞肺癌的发展
Wei Liu1, Dujuan Qiao2, Jia Chen3
1Department of Critical Care Medicine, Tangdu Hospital of Air Force Military Medical University, Xi'an, China.
Translational lung cancer research
|March 21, 2025
概括
阿司匹林通过上调调节甘酸氨基醇高密度脂结合蛋白1 (GPIHBP1) 来抑制非小细胞肺癌 (NSCLC). 这种机制涉及GPIHBP1与CD36相互作用,抑制瘤生长和转移.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肺癌是癌症死亡的主要原因之一.
- 阿司匹林显示出抗癌作用,但其在非小细胞肺癌 (NSCLC) 中的作用需要澄清.
- 葡萄糖酸氨基醇高密度胆固醇结合蛋白1 (GPIHBP1) 和CD36参与脂质代谢和癌症进展.
研究的目的:
- 阐明阿司匹林抑制NSCLC扩散和转移的机制.
- 研究GPIHBP1在阿司匹林在NSCLC中的抗癌作用中的作用.
主要方法:
- 用RNA测序分析用阿司匹林或不用阿司匹林治疗NSCLC患者组织的分析.
- 免疫组织化学,西部抹迹和qRT-PCR来评估GPIHBP1的表达.
- 功能性测试和异种移植模型评估GPIHBP1在NSCLC进展和转移中的作用.
主要成果:
- 阿司匹林治疗提高了NSCLC组织中的GPIHBP1的调节.
- 过度表达GPIHBP1抑制了NSCLC细胞迁移,增殖和上皮细胞-介质细胞过渡,同时促进了细胞亡.
- GPIHBP1直接与CD36相互作用,其敲击破坏了CD36的局部化,促进了瘤的进展.
结论:
- 阿司匹林通过一种依赖GPIHBP1的途径抑制NSCLC的发展.
- GPIHBP1与CD36的相互作用对其抗癌作用至关重要.
- GPIHBP1代表了NSCLC治疗的潜在治疗标.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
441
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
441
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
140
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
140